This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
Medpace Growth Trends Show How CRO Demand Is Shifting in 2026
by Moumi Mondal
MEDP's 2026 outlook highlights shifting CRO demand, longer award-to-revenue timing and steady margins, while AI investment delays near-term productivity gains.
MEDPNegative Net Change CRLNegative Net Change IQVNegative Net Change
medical medical-devices
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
by Zacks Equity Research
DXCM's expanding CGM reach, G7 15 Day rollout and international momentum support growth, but can reimbursement and cost risks temper the outlook?
DXCMNegative Net Change ISRGNegative Net Change WSTNegative Net Change GMEDNegative Net Change
medical medical-devices
Medpace Stock Outlook Turns on Backlog Quality and Cancellations
by Moumi Mondal
MEDP's outlook hinges on whether strong backlog quality and metabolic demand can offset rising cancellations and softer proposal activity.
MEDPNegative Net Change CRLNegative Net Change IQVNegative Net Change
medical medical-devices
Heico Corporation (HEI) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
HEINegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
WST Stock Up Nearly 33% YTD: Will the Uptrend Continue in the Rest of 2026?
by Zacks Equity Research
WST has surged nearly 33% YTD as strong earnings, GLP-1 demand and biologics growth fuel momentum that could extend through 2026.
WSTNegative Net Change BDXNegative Net Change BAXNegative Net Change ABBVPositive Net Change
medical medical-devices
Butterfly Network Expands Handheld Ultrasound Reach in Brazil
by Zacks Equity Research
BFLY launches Butterfly iQ+ and iQ3 in Brazil, expanding its handheld ultrasound reach into a major Latin American medical device market.
BFLYNegative Net Change WSTNegative Net Change GMEDNegative Net Change BTSGPositive Net Change
medical medical-devices
Ecolab Closes CoolIT Acquisition, Strengthens AI Cooling Portfolio
by Zacks Equity Research
ECL's $4.75B CoolIT acquisition boosts its AI cooling portfolio and positions High-Tech as a major long-term growth engine.
ECLNegative Net Change ISRGNegative Net Change WSTNegative Net Change GMEDNegative Net Change
medical medical-devices
Should You Buy Evolent Health (EVH) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
EVHPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Travel + Leisure Co. (TNL) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
TNLNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Continue to Hold ILMN Stock in Your Portfolio?
by Zacks Equity Research
Illumina builds on strong NovaSeq X demand and clinical sequencing momentum, but China weakness and cost pressures keep challenges in focus.
ILMNNegative Net Change ALGNNegative Net Change IARTNegative Net Change GMEDNegative Net Change
medical medical-devices